Lintuzumab Ac-225

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameLintuzumab Ac-225
Drug Alias NameActinium-225 (225Ac)-LintuzumabAc225 monoclonal antibody M195Lintuzumab-Ac225SMART-actinium-225-M-195Actinium-225-labelled HuM195 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionIonising radiation emittersMyeloid cell surface antigen CD33 inhibitors
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsMultiple MyelomaGliosarcomaGlioblastoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteActinium Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsGliosarcomaGlioblastomaGlioma +[4] 
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksWikipedia